Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Top Cited Papers
- 8 October 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (15), 1413-1424
- https://doi.org/10.1056/nejmoa2022190
Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.Keywords
Funding Information
- Boehringer Ingelheim
- Eli Lilly
This publication has 10 references indexed in Scilit:
- Natriuretic Peptides as Inclusion Criteria in Clinical TrialsJACC: Heart Failure, 2020
- SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of ActionDiabetes Care, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionThe New England Journal of Medicine, 2019
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trialEuropean Journal of Heart Failure, 2019
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusCirculation, 2019
- Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionCirculation, 2019
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialCirculation, 2019
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysisBMJ Open, 2019
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017